Neoadjuvant Therapy, Pancreatic Cancer, Robotic Surgery
Conditions
Keywords
Pancreatic cancer, Neoadjuvant therapy, Robotic surgery, Open surgery
Brief summary
The feasibility and safety of minimally invasive surgery in cases after neoadjuvant therapy were unclear. It is worth exploring the safety of robotic resection for pancreatic cancer following neoadjuvant therapy. The investigators investigated the comparative outcomes of robotic and open surgery in the management of pancreatic cancer after NAT, exploring the feasibility and safety of robotic procedures in complex cases of pancreatic cancer, and providing evidence-based guidance for clinical practice.
Detailed description
Currently, most studies focus on upfront resectable pancreatic cancer, benign or low-grade malignant tumors, demonstrating that robotic surgery can shorten postoperative hospital stays, reduce intraoperative blood loss, and achieve oncological outcomes comparable to open surgery. The feasibility and safety of minimally invasive surgery in cases after NAT were unclear. Both the Miami international evidence-based consensus and the Brescia international validated European guidelines indicate that current data are insufficient to recommend minimally invasive approaches for pancreatic cancer resection following NAT, highlighting the need for additional research. Therefore, it is worth exploring the safety of robotic resection for pancreatic cancer following NAT. The investigators investigated the comparative outcomes of robotic and open surgery in the management of pancreatic cancer after NAT, exploring the feasibility and safety of robotic procedures in complex cases of pancreatic cancer, and providing evidence-based guidance for clinical practice.
Interventions
None listed
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age over 18 years. * Received neoadjuvant chemotherapy. * Postoperative pathology confirmed pancreatic cancer. * Underwent either open or robotic surgery.
Exclusion criteria
* Intraoperative discovery of unresectable tumor or presence of distant metastasis. * ASA score ≥ 4.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall complication | Until the 90 days after surgery | The complication occurred within 90 days after the surgery |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinically relevant postoperative pancreatic fistula | Until the 90 days after surgery | Grade B or C pancreatic fistula within 90 days after surgery |
| Postoperative pancreatectomy hemorrhage | Until the 90 days after surgery | Hemorrhage occurred within 90 days after surgery |
| Disease-free survival | Up to 2 years after the surgery | The length of time from the completion of surgery until the recurrence of cancer, the occurrence of metastasis, death from any cause, or to the last follow-up. |
| Overall survival | Up to 2 years after surgery | The length of time from the date of surgery to death from any cause or to the last follow-up. |
Countries
China
Outcome results
None listed